engleski

Visfatin is not associated with inflammatory markers in patients on hemodialysis

Cardiovascular events are a major cause of death in patients with end-stage renal disease. Endothelial dysfunction represents a key event in atherosclerosis development and has been implicated in the pathophysiology of different forms of cardiovascular disease, including chronic kidney disease. In recent years, visfatin, a ubiquitous adipokine, has been described as a potent marker of endothelial inflammation and dysfunction. The aim of the study was to investigate the association of visfatin with well-known markers of inflammation and endothelial dysfunction. Serum and plasma samples from 66 patients (40 males and 26 females) treated by hemodialysis were analysed for visfatin, fibrinogen, CRP, PAI-1 levels. Visfatin was determined by ELISA method while CRP, fibrinogen and PAI-1 were obtained by standard laboratory methods. We observed statistically significant correlation between visfatin level and fibrinogen (r = 0.51 ; p = 0.008) and the time on dialysis in female patients (r = 0.70 ; p  0.001). PAI-1 and CRP did not correlate with visfatin in males nor in females. Conclusions: Visfatin is correlated with time on dialysis and with fibrinogen only in female dialysis patients. To confirm this, further studies are needed with a higher number of patients.

endothelial dysfunction ; fibrinogen ; hemodialysis ; inflammation ; PAI-1 ; visfatin

(Zapis je netocan (?) - rada pod navedenim naslovom (+ autor) nema u CC-u niti WoS-u ; naslov casopisa i numericki podaci (?) ; admin 2015-09-04.) pronadjen u bazama 3.3.2017. admin